Search
for
Sort by
Research 751–780 of 777
- Successful Treatment of Extensive Ritlecitinib-Refractory Alopecia Areata with Upadacitinib
- Baricitinib Induced Hypoglycemic Seizures in a Patient with Hair Loss and Type I Diabetes Mellitus: A Case Report
- Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED
- 448 Combined therapeutic approach: Inhibition of MMP-9 and JAK Signaling Synergistically Prevents Depigmentation in Experimental Vitiligo
- 0480 Upadacitinib monotherapy for treatment of pyoderma gangrenosum: A case series
- Topical Ruxolitinib in Combination with Oral Minoxidil Results in Hair Regrowth in a Patient with Central Centrifugal Cicatricial Alopecia and Concomitant Traction Alopecia
- Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
- S3886 Concurrent Management of Crohn's Ileitis and Alopecia Universalis With Upadacitinib
- JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
- 59 Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- Scarring hair follicle destruction is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
- Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
- Emerging role of baricitinib in dermatology practice: All we need to know!
- Concomitant management of alopecia universalis and ulcerative colitis with upadacitinib
- Treatment of concomitant alopecia areata and systemic lupus erythematosus with ivarmacitinib: a case report and literature review
- Ruxolitinib: A novel molecule in the management of dermatological disorders
- Modern dermatology brings treatment even for alopecia areata
- 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
- 808 Lichen planus single cell and spatial profiling of cutaneous lichen planus treated with baricitinib
- Baricitinib in Alopecia Areata: Real-Life Changes in Lipid Profile and Hematologic Inflammation Indices at 52 weeks
- 397 Predictive modeling of drug response and mechanism of action in alopecia areata clinical trials
- Use of Jak Inhibitors in the Treatment of Alopecia Areata
- Effects of biomaterials derived from germinated hemp seeds for stressed hair stem cells and immune cells
- 056 IKZF1 and IKAROS overexpression contributes to the pathogenesis of alopecia areata
- Mesenchymal-epidermal interactions in hair follicle cycling and regeneration
- <i>IKZF1</i> and Ikaros Overexpression Results in Alopecia Areata‐Like Phenotype in Mice
- Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials